CD8A and neoplasm: ACM derived from OGJ patients with early-stage tumours and late-stage tumours significantly increased the expression of CD62L on the surface of CD8+ T cells compared with untreated cells (untrx: 23.26 ± 8.2 vs. early-stage: 46.05 ± 8.4%, p = 0.01, late-stage: 47.08 ± 9.3%, p = 0.005) (Fig. 1A).